Investment Highlights for GeoVax Labs, Inc.
GeoVax Labs, Inc.
1900 Lake Park Drive, Suite 380
Smyrna, GA 30080
https://www.geovax.com/
You Might Also Like...
Investment Highlights for
GeoVax Labs, Inc. (GOVX-OTC)
- On August 6, 2024, GeoVax announced second quarter 2024 financial results and provided a corporate update. Net loss for the three months ended June 30, 2024 was $5,064,042, or $1.99 per share versus $5,927,620, or $3.79 per share, for the comparable period in 2023.
- GeoVax has made significant strides during the first half of 2024, highlighted by the recent receipt of the BARDA Project NextGen award to evaluate GEO-CM04S1, the Company's next-generation, dual-antigen COVID-19 vaccine. In addition, GeoVax has partnered with Allucent, a global CRO, to initiate the trial and advance GEO-CM04S1 into the BARDA-funded 10,000-patient Phase 2b clinical study. With over $350 million secured for the trial, this U.S. government recognition not only validates GeoVax's clinical strategy but also provides the necessary resources to accelerate its development.
- GEO-CM04S1 has demonstrated potent, broadly reactive, and long-lasting antibody and T cell immune responses in individuals with both healthy and compromised immune systems. Given the increasing understanding that robust T cell responses are crucial for antibody recall and protection against severe disease and hospitalization, GeoVax believes that GEO-CM04S1 stands-out as a next-generation COVID-19 vaccine with the ability to greatly enhance patient care.
- With support from an oncology clinical advisory committee and following a thorough review of Gedeptin’s safety and efficacy data, GeoVax is poised to advance an expanded Phase 2 clinical trial evaluating Gedeptin in patients with first-recurrence head and neck cancer.
- GeoVax continues to strengthen its global intellectual property position, with over 115 granted or pending patent applications spread over twenty-four patent families.
- The Company anticipates forming business partnerships and collaborations to support the global development, commercialization, and distribution of its products.
- GeoVax reported cash balances of $1,561,712 at June 30, 2024 versus $6,452,589 at December 31, 2023.